Literature DB >> 9180347

Effect of valproate on the metabolism of the central nervous system.

J P Bolaños1, J M Medina.   

Abstract

The effects of valproate on brain energy and lipid metabolism is reviewed. Increasing evidence suggests that valproate uses the monocarboxylic acid carrier in order to cross the blood brain barrier (BBB) and the neural cell plasma membranes. The uptake of valproate into the brain through this mechanism would compete with the uptake of energy precursors, such as the monocarboxylic acids 3-hydroxybutyrate, lactate or pyruvate and with some amino acids, but not with glucose. This could impair brain fuel utilization, specially during the neonatal period or childhood, when lactate or 3-hydroxybutyrate furnishes alternative substrates to glucose for the brain. It is concluded that valproate interference with energy metabolism may have implications for the therapeutic action of the drug, stressing the possibility that valproate-mediated alterations in brain lipid synthesis may contribute to the pharmacological action of the drug.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180347     DOI: 10.1016/s0024-3205(96)00687-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.

Authors:  Yong Tang; Adly Yacoub; Hossein A Hamed; Andrew Poklepovic; Gary Tye; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2012-05-01       Impact factor: 4.742

2.  Colloidal microgels in drug delivery applications.

Authors:  Serguei V Vinogradov
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

3.  Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.

Authors:  Richard P Bazinet; Margaret T Weis; Stanley I Rapoport; Thad A Rosenberger
Journal:  Psychopharmacology (Berl)       Date:  2005-12-13       Impact factor: 4.530

4.  Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.

Authors:  Mikko Gynther; Lauri Peura; Monika Vernerová; Jukka Leppänen; Jussi Kärkkäinen; Marko Lehtonen; Jarkko Rautio; Kristiina M Huttunen
Journal:  Neurochem Res       Date:  2016-07-14       Impact factor: 3.996

5.  Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat.

Authors:  Richard P Bazinet; Jagadeesh S Rao; Lisa Chang; Stanley I Rapoport; Ho-Joo Lee
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

6.  Valproyl-CoA and esterified valproic acid are not found in brains of rats treated with valproic acid, but the brain concentrations of CoA and acetyl-CoA are altered.

Authors:  Joseph Deutsch; Stanley I Rapoport; Thad A Rosenberger
Journal:  Neurochem Res       Date:  2003-06       Impact factor: 3.996

Review 7.  Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

Authors:  Philippe E R Lheureux; Andrea Penaloza; Soheil Zahir; Mireille Gris
Journal:  Crit Care       Date:  2005-06-10       Impact factor: 9.097

8.  Chronotolerance study of the antiepileptic drug valproic acid in mice.

Authors:  Wafa Ben-Cherif; Ichrak Dridi; Karim Aouam; Mossadok Ben-Attia; Alain Reinberg; Naceur A Boughattas
Journal:  J Circadian Rhythms       Date:  2012-05-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.